Navigation Links
Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
Date:5/14/2008

eriod in 2007. The change included $3.1 million in increased costs related to the development of R3487/MEM 3454 and R4996/MEM 63908, and a $0.9 million increase related to manufacturing and preclinical costs associated with the 5-HT6 antagonist program, offset by a $3.4 million decrease in costs associated with the clinical development of MEM 1003.

General and administrative expenses for the quarter ended March 31, 2008 were $2.9 million, compared to $2.3 million for the same period in 2007. The change included an increase of $0.2 million in personnel and personnel-related costs, a $0.2 million increase in legal fees, and a $0.2 million increase in outside services.

At March 31, 2008, the Company had cash, cash equivalents and marketable securities of approximately $27.5 million, compared to $38.2 million at the end of 2007. The Company continues to expect that its existing cash, cash equivalents, and marketable securities, together with payments expected to be made under its collaboration agreements, should be sufficient to fund operating expenses, scheduled debt obligations and capital equipment requirements into the first half of 2009.

First Quarter Highlights and Recent Developments

-- Roche Opt-in for R3487/MEM 3454. In May, Roche exercised its option to

license R3487/MEM 3454, Memory Pharmaceuticals' lead nicotinic alpha-7

receptor agonist, for further development and commercialization in

psychiatric and neurological disorders. The option exercise triggers a

$6.0 million milestone payment and entitles Memory Pharmaceuticals to

future payments upon the achievement of additional milestones and

royalties on product sales, including a $17.0 million milestone payment

upon the completion of the ongoing Phase 2a study in cognitive

impairment associated with schizophrenia. In addition, Memory

Pharmaceuticals retains an option to co-promote R3487/MEM 345
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
2. Memory in artificial atoms
3. Memory Pharmaceuticals Receives Nasdaq Notification
4. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
5. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
6. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
7. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
10. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
11. ASU researchers improve memory devices using nanotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... TOLEDO’s newly improved XS balance line includes analytical ... a dual range microbalance . As a revolutionary ... delivers results up to twice as fast, even in ... mean users no longer need to suffer the stresses ... of the balance. Barbara Bienlein, medical specialist and managing ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Weighing ... quality of the final product. However, while the ... regulatory frameworks such as Good Manufacturing Practices (GMP) ... responsibility of the manufacturer to interpret these guidelines ... weighing performance quality. METTLER TOLEDO experts have created ...
(Date:10/1/2014)... City, CA (PRWEB) October 01, 2014 As ... it leaves no room for doubt that this century would ... innovations in the field of medicine science. The fact that ... problems is not unknown to the scientific community. Almost half ... pollution and therefore can be prevented with medical care and ...
(Date:10/1/2014)... 2014 In response to its ... address sales, training and consumer engagement challenges, ... mobile applications to turn their clients’ visions into ... customized mobile app creations, are now featured on ... partnership with Toyota, StudioPMG created a robust cross-platform ...
Breaking Biology Technology:METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3Comply with Weighing-Related Regulations in Pharma Manufacturing 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3Digital Agency Studio PMG Launches New Case Studies on Website 2
... is,strengthening its customer-focused biomarker services portfolio to,pharmaceutical, ... Xie will lead those efforts as Battelle,s ... a suite of biomarker services, including biomarker,discovery, ... clients,better define molecular mechanisms of diseases, toxicity, ...
... against management - with six million, votes revoked ... change rules, TORONTO, June 25 /PRNewswire/ - The ... be in court today and will seek a,declaration that ... Meeting,was illegally held and will request that a proper ...
... probiotic ingredient, GanedenBC30, to power new raisin bran probiotic muffins. ... ... Main Street Gourmet, one of the fastest growing manufacturers of gourmet ... muffin fortified with the high-survivability probiotic, GanedenBC30 (Bacillus coagulans ...
Cached Biology Technology:Battelle Selects Xie to Develop Biomarker Services 2Main Street Gourmet Launches New Probiotic Muffins 2Main Street Gourmet Launches New Probiotic Muffins 3
(Date:9/30/2014)... The National Institutes of Health (NIH) awarded ... to develop an electrode array system that will ... works through unprecedented resolution and scale. , LLNL,s ... support President Obama,s BRAIN (Brain Research through ... effort to revolutionize our understanding of the human ...
(Date:9/30/2014)... reports positive results of a phase 1 clinical ... lung cancer marked by rearrangement of the gene ROS1. ... non-small cell lung cancer testing positive for ROS1 gene ... complete responses and 33 partial responses. Median progression-free survival ... resume its growth after being slowed by treatment ...
(Date:9/30/2014)... it comes to using marijuana, new research, involving mice ... Journal of Leukocyte Biology , suggests ... that you should. That,s because a team of Italian ... do serious long-term damage to the immune system. This ... diseases, such as multiple sclerosis, inflammatory bowel disease and ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Adolescent exposure to thc may cause immune systems to go up in smoke 2
... waves, known as gamma oscillations, for more than 50 ... memory. Now, for the first time, MIT researchers and ... by shining laser light directly onto the brains of ... developed technology known as optogenetics, which combines genetic engineering ...
... Aware, Inc. (Nasdaq: AWRE ), a ... announced the final results of its modified Dutch Auction ... City time, on Friday, April 17, 2009.In accordance with ... has accepted for purchase 3,500,252 shares of its common ...
... April 23, 2009 -- Deteriorating screws in bridges, fish that ... treat disease, the detected comeback of a long-gone whale, the ... teach us about cowardice. These are just a few ... meeting of the Acoustical Society of America (ASA), which convenes ...
Cached Biology News:MIT: Making waves in the brain 2Aware, Inc. Announces Final Results of Dutch Auction Tender Offer 2Aware, Inc. Announces Final Results of Dutch Auction Tender Offer 3Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 2Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 3Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 4Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 5Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 6Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 7Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 8Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 9Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 10Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 11Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 12Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 13Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 14Laughing hyenas, wailing levees, the sound of cheese and blaring bagpipes 15
PKC (pSer345), phospho-specific...
PE Rat anti-Hu CD267 Storage Temperature: Refrigerate(2 to 8C)...
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
ASCIZ...
Biology Products: